Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$66.81 - $80.83 $2.66 Million - $3.22 Million
39,880 Added 9.65%
453,264 $35.4 Million
Q1 2024

May 03, 2024

BUY
$61.03 - $69.57 $5.97 Million - $6.8 Million
97,780 Added 30.98%
413,384 $28 Million
Q4 2023

Feb 09, 2024

BUY
$61.89 - $69.28 $298,619 - $334,276
4,825 Added 1.55%
315,604 $21.3 Million
Q3 2023

Nov 13, 2023

SELL
$64.85 - $71.7 $1.39 Million - $1.54 Million
-21,430 Reduced 6.45%
310,779 $21 Million
Q2 2023

Aug 03, 2023

SELL
$69.91 - $75.81 $3.17 Million - $3.44 Million
-45,403 Reduced 12.02%
332,209 $23.8 Million
Q1 2023

May 12, 2023

SELL
$63.15 - $71.6 $315,244 - $357,427
-4,992 Reduced 1.3%
377,612 $26.2 Million
Q4 2022

Feb 13, 2023

SELL
$54.21 - $70.44 $1.34 Million - $1.73 Million
-24,627 Reduced 6.05%
382,604 $25.9 Million
Q3 2022

Nov 07, 2022

BUY
$53.02 - $135.75 $3.3 Million - $8.45 Million
62,263 Added 18.05%
407,231 $22.3 Million
Q2 2022

Aug 12, 2022

SELL
$59.26 - $71.14 $2 Million - $2.4 Million
-33,796 Reduced 8.92%
344,968 $22.8 Million
Q1 2022

May 11, 2022

SELL
$55.72 - $67.12 $5,627 - $6,779
-101 Reduced 0.03%
378,764 $25.1 Million
Q4 2021

Feb 02, 2022

BUY
$54.02 - $63.83 $1 Million - $1.18 Million
18,543 Added 5.15%
378,865 $22.1 Million
Q3 2021

Nov 09, 2021

SELL
$55.56 - $60.79 $500,928 - $548,082
-9,016 Reduced 2.44%
360,322 $21.6 Million
Q2 2021

Aug 06, 2021

SELL
$48.42 - $60.18 $1.43 Million - $1.77 Million
-29,477 Reduced 7.39%
369,338 $22.1 Million
Q1 2021

May 10, 2021

SELL
$47.16 - $54.44 $5.11 Million - $5.9 Million
-108,352 Reduced 21.36%
398,815 $19.8 Million
Q4 2020

Feb 12, 2021

BUY
$48.52 - $58.02 $24.6 Million - $29.4 Million
507,167 New
507,167 $25.4 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Bi Asset Management Fondsmaeglerselskab A Portfolio

Follow Bi Asset Management Fondsmaeglerselskab A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.